“Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|7|1|56-64

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.7, Iss.1, 2011-02, pp. : 56-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management Strategies for Hormone-Refractory Prostate Cancer

By Attard Gerhardt   de Bono Johann S.   Parker Christopher C.   Horwich Alan  

American Journal of Cancer, Vol. 5, Iss. 3, 2006-01 ,pp. : 163-169

Adis International

Access to resources Recommend Favorite

Somatostatin analogs for the treatment of neuroendocrine tumors

By Culler Michael   Öberg Kjell   Arnold Rudolf   Krenning Eric   Sevilla Isabel   Díaz José  

Cancer and Metastasis Reviews, Vol. 30, Iss. 1, 2011-03 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the androgen receptor in hormone-refractory prostate cancer – new concepts

By Eder Iris E   Haag Petra   Bartsch Georg   Klocker Helmut  

Future Oncology, Vol. 1, Iss. 1, 2005-02 ,pp. : 93-101

Future Medicine

Access to resources Recommend Favorite

The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 3, 2007-11 ,pp. : 203-211

Bentham Science Publishers

Access to resources Recommend Favorite

Hormonal prevention of prostate cancer

By Brawley O.W.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 1, 2003-01 ,pp. : 67-72

Elsevier

Access to resources Recommend Favorite